Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
The purpose of this study is to use long-term administration of a low molecular weight
heparin (tinzaparin) for primary treatment and secondary prophylaxis of venous
thromboembolism in patients with cancer. We will determine the efficacy (recurrent VTE) and
safety (major hemorrhage) of this approach. Secondarily, we will analyze the outcome of
patients in terms of survival and response to therapy versus matched controls. We will also
determine baseline levels of markers of hemostasis, fibrinolysis, and angiogenesis and will
follow changes with treatment as well as correlate levels of these plasma markers with
outcomes, including recurrent venous thromboembolism, major hemorrhage,and survival.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Development of recurrent venous thromboembolism and major hemorrhage.
up to 6 months on treatment
Yes
United States: Institutional Review Board
0S-04-5
NCT00981903
July 2005
October 2014
Name | Location |
---|---|
University of Southern California | Los Angeles, California 90033 |
Cornell Weill Scholl of Medicine | New York, New York 10021 |